



HAL
open science

Nuclear receptors connect progenitor transcription factors to cell cycle control

Marta Neto, Marina Naval-Sánchez, Delphine Potier, Paulo S Pereira, Dirk Geerts, Stein Aerts, Fernando Casares

► **To cite this version:**

Marta Neto, Marina Naval-Sánchez, Delphine Potier, Paulo S Pereira, Dirk Geerts, et al.. Nuclear receptors connect progenitor transcription factors to cell cycle control. *Scientific Reports*, 2017, 7 (1), pp.2287-2301. 10.1038/s41598-017-04936-7 . hal-03390675

HAL Id: hal-03390675

<https://hal.science/hal-03390675>

Submitted on 21 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SCIENTIFIC REPORTS

OPEN

Nuclear receptors connect progenitor transcription factors to cell cycle control

Marta Neto^{1,3,4}, Marina Naval-Sánchez², Delphine Potier², Paulo S. Pereira^{3,4}, Dirk Geerts⁵, Stein Aerts² & Fernando Casares¹

The specification and growth of organs is controlled simultaneously by networks of transcription factors. While the connection between these transcription factors with fate determinants is increasingly clear, how they establish the link with the cell cycle is far less understood. Here we investigate this link in the developing *Drosophila* eye, where two transcription factors, the MEIS1 homologue *hth* and the Zn-finger *tsh*, synergize to stimulate the proliferation of naïve eye progenitors. Experiments combining transcriptomics, open-chromatin profiling, motif analysis and functional assays indicate that these progenitor transcription factors exert a global regulation of the proliferation program. Rather than directly regulating cell cycle genes, they control proliferation through an intermediary layer of nuclear receptors of the ecdysone/estrogen-signaling pathway. This regulatory subnetwork between *hth*, *tsh* and nuclear receptors might be conserved from *Drosophila* to mammals, as we find a significant co-overexpression of their human homologues in specific cancer types.

The programs for organ development are encoded in organ specification networks. In these networks, transcription factors (TFs) tightly control the specification of progenitor cells and their proliferation to ensure that the right types and amounts of cells are produced. Several organ-specification networks have been described in detail in the past years in vertebrates and invertebrates^{1–6}. However, how transcription factors act upon the cell cycle machinery to regulate progenitor cell proliferation is still poorly understood. To investigate this issue we have resorted to the developing *Drosophila* eye, for which a detailed transcriptional network is available^{6–8}.

In the fly eye primordium, eye progenitors are specified by the co-expression of a set of transcription factors: the two *Drosophila* Pax6 genes *eyeless* (*ey*) and *twin of eyeless* (*toy*), the TALE-class homeodomain *homothorax* (*hth*) and the Zn-finger encoding gene *teashirt* (*tsh*)^{6,9,10}. This gene expression combination is transient: the undifferentiated, proliferative state of progenitors is maintained as long as they express *hth*. Accordingly, the forced maintenance of *hth* blocks retina differentiation. In its progenitor role, *hth* is known to interact with *tsh*¹⁰. One important aspect of this interaction is that it is synergistic. Maintenance of *hth* stalls differentiation, while maintaining *tsh* only causes a mild retinal differentiation impairment (see below). However, maintaining the expression of both TFs (“*hth* + *tsh*”) results in large tumor-like overgrowths formed by progenitor-like cells^{10,11}. (see Results below). This suggests that *hth* + *tsh* together control the cell cycle machinery, directly or indirectly.

Interestingly, the vertebrate *hth* homologues, the MEIS gene family, not only are progenitor transcription factors that play essential roles during development^{12–17}, but their elevated expression has been associated to a number of tumor types in mice and humans^{18–28}.

The synergistic growth-inducing ability of Hth and Tsh has been attributed, at least in part, to their direct protein interaction with Yki¹¹, the nuclear effector and transcriptional co-activator of the Salvador-Warts-Hippo tumor suppressor pathway²⁹. Only one direct transcriptional target of the Hth:Tsh:Yki complex has been functionally validated to date, though, the miRNA-encoding gene *bantam* (*ban*)¹¹. Even though *ban* is expected to have a rather pleiotropic effect^{30,31}, on its own it does not account for the large overgrowths induced by

¹CABD, Andalusian Centre for Developmental Biology, CSIC-UPO-JA, 41013, Seville, Spain. ²School of Medicine, University of Leuven, box 602 3000, Leuven, Belgium. ³IS - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135, Porto, Portugal. ⁴IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135, Porto, Portugal. ⁵Department of Medical Biology L2-109, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Correspondence and requests for materials should be addressed to S.A. (email: stein.aerts@kuleuven.vib.be) or F.C. (email: fcasfer@upo.es)




Figure 1. Forced maintenance of *hth* and *tsh* expression results in overgrowth and differentiation arrest. Late third instar (L3) eye discs (A–D) and adult heads (A'–D' and A''–D'') from control (*optix > GFP*) and *hth*- (*optix > hth*), *tsh*- (*optix > tsh*) or *hth* + *tsh*- (*optix > hth + tsh*) expressing animals. The GFP expression driven by *optix > (optix2/3-GAL4; UAS-GFP)* is shown in the inset in (A). Discs are stained with anti-Eya and anti-Hth. Anterior is left, dorsal is up (this orientation will be maintained throughout). (A'–D') Lateral views of adult heads of the same genotypes as above. (A''–D'') SEM images of lateral views of adult heads of the corresponding genotypes. Overexpression of *hth* (*optix > hth*) results in a reduced eye disc area and smaller adult eye (B,B''). *tsh*-overexpressing flies (*optix > tsh*) show almost normal discs and retinal morphology (C–C''). However, overexpression of *hth* and *tsh* (*optix > hth + tsh*), results in overgrown eye discs showing abnormal folds. Adult heads develop a small retinal patch and an overgrowth of indistinct cuticle (D,D'').

Hth:Tsh:Yki. Therefore, a global picture of the transcriptional changes specifically induced by *hth* and *tsh* and how these are connected to tissue growth is still lacking.

Here we have analyzed the global impact that *hth* + *tsh* have on the developing eye to establish links between these transcription factors and target genes, using genome-wide gene expression and open chromatin profiling, together with computational methods. The resulting picture of this epigenomic analysis is one in which the up-regulation of large numbers of cell cycle genes may be due to the primary regulation of a few potentially direct targets, that include a subset of components of the ecdysone/estrogen pathway. These nuclear receptors would then amplify the *hth* + *tsh* response by directly affecting cell cycle genes, as these genes show a signature of nuclear receptor binding. We tested this prediction functionally and showed that indeed *Ecr*, the ecdysone receptor, and the nuclear receptors *Hr46/DHR3* and *ftz-f1* were required for *hth* + *tsh*-driven tumor-like overgrowth. Therefore, growth control by progenitor TFs Hth and Tsh would be funneled through nuclear receptors, acting as intermediaries. The connection between *hth*, *tsh* and nuclear receptors might extend beyond *Drosophila*, as we found a significant co-overexpression of the human homologues of *hth*, *tsh* and *ftz-f1*, the MEIS1, TSHZ and NRA52 genes, in specific cancer cell lines and tumors.

Results

Perturbations of progenitor transcription factors result in tissue overgrowth. During development, the expression of eye progenitor transcription factors is transient to allow cell cycle stop and differentiation. However, the forced maintenance in the eye primordium of two of these transcription factors simultaneously, *hth* and *tsh*, cause the tumor-like overgrowth of progenitor-like cells¹⁰. To analyze how the combined expression of these two factors drives proliferation, we expressed *hth* and *tsh*, either alone or in combination, using the eye-specific GAL4 driver *optix2/3-GAL4* (or “*optix >*”). *optix >* is specifically active in undifferentiated cells of the eye disc (Fig. 1A and Suppl. Figure 1 and ref. 32). Therefore, the effects of gene manipulations driven by *optix >* reflect effects on the undifferentiated population. While when *hth* or *tsh* were expressed alone no overproliferation was produced (*optix > GFP:hth* and *optix > tsh*, respectively; Fig. 1A–C), coexpression of both TFs in *optix > GFP:hth + tsh* (“*hth + tsh*”) produced disc overgrowths. The overgrown tissue does not differentiate into retina. This resulted, in the adult, in heads with a very small eyes surrounded by overgrown indistinct cuticle (Fig. 1A',A''–D',D'').




Figure 2. Transcriptomic profile of *hth* + *tsh* cells. **(A)** Gene Ontology enrichment of genes up-regulated in *hth* + *tsh* compared to control eye discs (EA). Analysis performed by GOrilla⁹⁷ on a ranked list of genes sorted by (signed) $-\log_{10}(\text{p-value})$. The sign indicates that up-regulated genes are on top ($\log_{2}\text{FC} > 0$) and down-regulated genes ($\log_{2}\text{FC} < 0$) are on the bottom of the list. **(B)** Heatmap with row-normalized expression values of the most significantly up-regulated cell-cycle related genes. **(C)** Motif enrichment on the up-regulated genes (770 genes, selected as the “leading edge” of the GOrilla analysis for cell cycle enrichment). Enrichment analysis is performed by i-cisTarget³³ and enriched motifs are clustered within i-cisTarget using STAMP¹⁰³. NES = Normalized Enrichment Score (>2.5 is significant). The Hth motif was not found enriched. **(D)** Heatmap of expression profiles of motif related Nuclear Receptor genes and Blimp-1, showing strongest up-regulation of EcR and *ftz-f1*, and strongest down-regulation of Hr46 and Blimp-1.

Cell cycle genes and nuclear receptors are altered downstream of Hth + Tsh. To obtain a global view of the impact that *hth* + *tsh* co-expression had on gene expression, we generated the transcriptional profiles of late third larval stage (L3) eye discs from control (*optix* > *GFP*) as well as *hth*-expressing (*optix* > *GFP:hth*), *tsh*-expressing (*optix* > *tsh*), and *hth* + *tsh*-expressing (*optix* > *GFP:hth* + *tsh*) larvae using RNA-seq (see Materials and Methods). Principal component analysis of the RNA-seq data (Suppl. Fig. 2A) showed that *optix* > *tsh* clustered closest to the control, in agreement with its weak phenotype. *optix* > *GFP:hth* and the two *optix* > *GFP:hth* + *tsh* replicates were clearly distinguished. Next, when differential gene expression (DE) between the *optix* > *GFP:hth* + *tsh* and control samples was analyzed, the majority of DE-genes were down-regulated (Suppl. Fig. 2B). GO-enrichment analysis of the 503 significantly down-regulated genes ($\text{p.adj} < 0.05$ and $\log_{2}\text{FC} < -1$) identified “generation of neurons” and “compound eye photoreceptor cell differentiation” as enriched terms (Suppl. Fig. 2C), in agreement with the vestigial retina that develops in *optix* > *GFP:hth* + *tsh* adults. On the other hand, among the functions associated to the upregulated genes were those related to “cell cycle” and “DNA replication” (Suppl. Fig. 2D), which agree with the over-proliferative phenotype observed in *optix* > *GFP:hth* + *tsh* eye discs. This enrichment is found in a set of 103 significantly up-regulated genes (DE-seq, $\text{p.adj} < 0.05$ and $\log_{2}\text{FC} > 1$), but is even stronger if the entire gene ranking is considered, whereby in the top 770 genes 74 cell cycle genes are recovered ($\text{p.adj} 10^{-32}$, see Fig. 2A). From the heatmap shown in Fig. 2B it can be observed that the cell cycle-related genes are up-regulated as a consequence of the synergistic action of *hth* and

tsh, since no up-regulation is observed when either *hth* or *tsh* are over-expressed alone. Among these genes we found key cell cycle regulators, such as *polo* kinase, *dp53* and *Rbf* and *Rbf2* (Fig. 2B). A list of DE-genes can be found in Suppl. Table 1.

In order to further analyse the effects of *hth* + *tsh* on cell cycle regulation, we generated *hth* + *tsh*-expressing clones and examined the expression of different cell cycle markers: the G1/S-phase *cyclin-E*, the G2/mitotic *cyclin-A* and the cyclin-dependent kinase inhibitor *dacapo* (*dap*). In agreement with their effect stimulating proliferation, *hth* + *tsh* coexpression induces *cyclin-A* and *cyclin-E* expression and represses *dap* expression in cell clones (Suppl. Fig. 3).

To identify transcription factors (TFs) that may control directly these DE genes we looked for TF binding site motif enrichment in the vicinity of the differentially expressed genes using *i-cisTarget*^{33,34} (See Materials and Methods). Down-regulated and up-regulated genes showed different motif enrichment: potential binding sites for E-box (top-enriched motif with a NES score of 4.73) and Glass (GI) (motif also enriched with a NES score of 3.17) were found associated to down-regulated genes (data not shown). E-box-binding bHLH proteins *Hairy*, *Daughterless*, *Emc* and *E(spl)*-family members are known to participate in the specification of retinal precursors, regulating, among other genes, *atonal*, another bHLH transcription factor required for the specification of the R8 founder photoreceptor precursor^{35–39}; *gl* encodes a five Zn-finger transcription factor required for the development of all photoreceptors⁴⁰. These results were expected, since *hth* + *tsh* cause a blockade of the retinal developmental program.

On the other hand, up-regulated genes showed enrichment in potential binding sites for a bHLH TF (possibly *Taiman*), and for the general transcriptional co-factors *Dref*⁴¹ and *Grainyhead*⁴². Interestingly, motifs for E2F and nuclear hormone receptors are also strongly enriched, including *EcR* (Ecdysone receptor), *ERR* (estrogen-related receptor), *ftz-f1*, *Hr46/DHR3* or *Hr39* (Fig. 2C). E2F is necessary for normal proliferation and DNA synthesis^{43–45} and the enrichment in E2F potential target genes might reflect the vigorous proliferation of *hth* + *tsh* cells. The enrichment of binding sites for nuclear hormone receptors of the *EcR* pathway in up-regulated genes was unexpected, and suggests that a critical subset of the up-regulated genes could be under the direct control of nuclear hormone receptors.

The finding of *EcR*/nuclear receptor-related motifs prompted us to investigate the expression profile of the members of the *EcR* signaling cascade differentially expressed specifically in *hth* + *tsh* cells (Fig. 2D). These included the nuclear receptors *EcR* and *ftz-f1* (up-regulated) and the nuclear receptor *Hr46/DHR3* and the transcriptional repressor *Blimp-1* (down-regulated), this latter also a regulator of the ecdysone pathway⁴⁶. We noted that this pattern of nuclear receptor gene expression, characterized by high *EcR/ftz-f1* and low *Hr46/Blimp-1* is typical of a low/moderate ecdysone signaling^{46–49}. Indeed, activity of the ecdysone pathway in L3 eye discs, monitored using an Ecdysone Response Element-lacZ (*EcRE*)⁵⁰, can be observed straddling the morphogenetic furrow (MF), but not in more anterior regions, where the *hth* + *tsh* progenitor cells reside⁵¹. To test whether *hth* + *tsh* could reduce ecdysone signaling, we generated *hth* + *tsh*-expressing clones in an *EcRE-Z* background. Clones that span the MF show reduced *EcRE-Z* activity, while clones located elsewhere do not modify this reporter's activity (Fig. 3A–C). Therefore, indeed co-expression of *hth* + *tsh* downregulates the response of cells to ecdysone signaling, and in a cell-autonomous manner.

Interestingly, we did not find an enrichment of *Hth* binding site (BS) motifs among the collection of *hth* + *tsh* DE genes (TGACA; <http://pgfe.umassmed.edu/ffs/>; note that a *Tsh* binding motif has not yet been described). The failure in finding *Hth* BSs could be explained by either one of two possibilities. First, *Hth* might bind to regulatory regions of many DE genes, but using a non-canonical BS. We find this unlikely, because all available experimental evidence (bacterial-1-hybrid in *Drosophila*, ChIP-seq in mouse, SELEX, protein binding microarrays, and manual curation) has retrieved the same binding motif for *Hth*/MEIS in invertebrates and vertebrates: the monomeric motif TGTC A or the palindromic dimer motif TGACA_{NN}TGTC A⁵². Neither of these two motifs was found enriched in the up- or down-regulated DE gene set. We further noted that the DE genes regulated by *hth* + *tsh* were not enriched in *Hth*-binding sites previously identified using ChIP-seq^{53,54}. Alternatively, *Hth* might bind using its canonical BSs, but only on a relatively small subset of DE genes (primary targets), which then would amplify *Hth* regulation through secondary (indirect) targets. In such a situation, motif enrichment searches would not detect the *Hth* motif as significantly enriched. With this idea in mind, we looked for candidate direct targets by analyzing activity changes in associated regulatory regions.

Open chromatin profiling confirms Nuclear Receptors as candidate regulators. Accessible chromatin regions are associated to active promoters and *cis*-regulatory elements (CREs). Therefore, we reasoned that changes in the activity of distal CREs overlapping *Hth* binding sites (from *Hth*-ChIP data), and located near DE genes would point to *hth* + *tsh* direct targets. To this end, we carried out open chromatin profiling using FAIRE-seq^{55–57}. Specifically, we compared the FAIRE-seq eye disc profiles of two control strains (see Materials and Methods) and *optix > GFP:hth*, *optix > tsh* and *optix > GFP:hth + tsh* (Suppl. Table 2 and Suppl. Fig. 4). We identified relatively few CREs with significantly altered chromatin accessibility. This finding was rather unexpected. First, the severe overgrowth phenotype and the large amount of differentially expressed genes suggested otherwise. Second, in another *Drosophila* model of eye overgrowth/cancer (induced by simultaneous expression of oncogenic *ras* and loss of *scribble*) dramatic chromatin changes have been described⁵⁷. Specifically, with a particular set of stringent parameters, we identified only 86 CREs showing significantly increased accessibility when *hth* + *tsh* were co-expressed ($\log_2(\text{FC}) > 1$ and ($p\text{-adj} < 0.05$)), and 87 with significantly decreased accessibility ($\log_2(\text{FC}) < 1$ ($p\text{-adj} < 0.05$)). The regions with decreased accessibility are significantly associated with down-regulated genes (Fig. 4A), mostly related to the loss of the differentiation program in the eye disc. On the other hand, only a handful of regions with increased accessibility are associated with down-regulated genes (Fig. 4B), of which *Hr46* and *Blimp-1* are the most prominent examples (Fig. 4B). We did not find a significant association between peaks with increased accessibility and up-regulated genes (Fig. 4B). We next used *i-cisTarget*




Figure 3. Co-expression of *hth + tsh* downregulate EcR signaling. *hth + tsh*-expressing clones (marked with GFP) induced in an Ecdysone Response Element-*lacZ* (EcRE-Z) background analyzed in L3 eye discs. *lacZ* expression is monitored with an anti- β galactosidase antibody (β gal). EcRE-Z is expressed straddling the morphogenetic furrow (dashed line) exclusively (A,A'). *hth + tsh*-clones overlapping the EcRE-Z domain repress its expression (B), while clones elsewhere do not (A,A'). (A) is a lower magnification view of the disc shown in (A') where the whole pattern of EcRE-Z can be seen. The EcRE-Z sinla is shown separately in the lower panels.

to identify TF motifs within the FAIRE peaks showing increased accessibility, and again found Nuclear Receptor motifs (in this case, among NRs the EcR motif is the strongest, see Suppl. Fig. 5), but did not identify the Hth motif as enriched in the set. However, the few CREs with increased accessibility located near the down-regulated genes *Hr46* and *Blimp-1*, show overlapping or nearby ChIP-peaks for Hth (data from embryos⁵⁸ and eye discs⁵⁹ suggesting that *hth + tsh* may be directly repressing these nuclear receptor genes (Fig. 4C,D). Interestingly, these peaks also overlap EcR binding sites (Fig. 4C,D).

So far these data indicate that *hth + tsh* progenitor-like cells drive a specific pattern of nuclear receptor expression, characteristic of low/moderate ecdysone signaling, and that this expression pattern could be playing a direct role in the *hth + tsh*-induced overgrowths by in turn controlling a large set of cell cycle genes. If this hypothesis were true, some of these nuclear receptors should be required for the *hth + tsh*-driven tissue overgrowth. In addition, their expression should be regulated by *hth + tsh in vivo*. We next tested these two assumptions in turn.

Functional analysis indicates that regulation of nuclear receptors EcR, *ftz-f1* and *Hr46/DHR3* controls *hth + tsh*-driven overgrowth. To test whether differentially expressed genes in the EcR pathway participated in controlling the *hth + tsh* induced overgrowth, we altered the expression levels of *EcR*, *Hr46/DHR3*, *ftz-f1* and *Blimp-1* in the *optix > GFP:hth + tsh* background, either through double-stranded RNAi-specific knock-downs, dominant negative forms (in the case of EcR) or by overexpression. When available, we used several different RNAis per gene (Suppl. Table 3). To evaluate whether varying the expression levels of a gene enhanced or suppressed the *hth + tsh*-driven phenotype, we took into consideration changes in size and extent of differentiation in eye discs and, in adults, we assessed retina size and amount of undifferentiated cuticle. In these experiments, we found strong interactions with *EcR*, *Hr46/DHR3* and *ftz-f1* (Figs 5 and 6 and Suppl. Fig. 7).

On its own, overexpression of *EcR* (*optix > EcRB1*) did not result in any abnormality (Suppl. Fig. 6). However, when EcR was co-overexpressed with *hth + tsh* (*optix > hth + tsh + EcR^{B1}*) the overgrowth of adult cuticle was exacerbated dramatically (Fig. 5A,C). This was also observed in the eye discs, with co-overexpression of *EcR* further increasing the overgrowth of the tissue (Fig. 5B,D). Co-overexpression of a dominant-negative form of the same receptor (*optix > hth + tsh + EcRB1^{W650A}*) caused adult lethality, so we analyzed the effects only on eye discs. *optix > EcRB1^{W650A}* discs exhibited moderately reduced retinal differentiation and eye disc size (46% smaller than *optix > GFP* control discs). The overgrowth in *optix > hth + tsh + EcRB1^{W650A}* discs was suppressed compared with *optix > hth + tsh* discs in a similar degree (*optix > hth + tsh + EcRB1^{W650A}* discs were 42% smaller than *optix > hth + tsh* discs) (Fig. 5E,F and Suppl. Fig. 8). This set of results indicates that EcR, the expression of which is increased in *hth + tsh* cells, contributes positively to the *hth + tsh*-driven tissue overgrowth.

When *Hr46* (Fig. 6A,B) or *ftz-f1* (Fig. 6A,D) were attenuated using RNAi, the *optix > hth + tsh* disc overgrowths were exacerbated. In the case of *Hr46/DHR3* and *ftz-f1*, it is important to note that neither of the




Figure 4. FAIRE-seq open chromatin profiling of *hth + tsh* cells. **(A)** Gene Set Enrichment Analysis (GSEA, ref. 100) compares gene expression changes with open chromatin changes. In the x-axis are all genes, ranked by the significance p-value of differential expression of control versus *hth + tsh* samples, with genes down-regulated in *hth + tsh* on the left, and genes up-regulated on the right. The tested gene sets (shown as black vertical lines) are genes with nearby (in 5 kb upstream and intronic space) FAIRE-seq peaks showing significant *decreased accessibility*. The correlation between both is highly significant (FDR < 0.001). **(B)** Similar plot, comparing changes in gene expression with genes showing nearby FAIRE-peaks with *increased accessibility*. In this case, the correlation is not significant, but the most down-regulated nuclear receptors Hr46 and Blimp-1 (indicated) are among the few genes showing peaks with increased accessibility. **(C,D)** Genomic view of Hr46 **(C)** and Blimp-1 **(D)** showing FAIRE-seq open chromatin profiling data for *optix > hth + tsh* (“HTH_TSH”), *optix > hth* (“HTH”) and control eye-antennal discs (EA) (EA_WT: black wiggle plot tracks); Hth ChIP-seq target regions in embryo and EA disc are shown with a red line; HTH-TSH versus WT differentially open chromatin peaks are highlighted with a cyan background; and prediction of binding sites within Hth ChIP peaks are shown as black ticks marked as “HTH_predicted_BS” (Cluster-Buster)¹⁰⁴ motif score >6 using FlyFactorSurvey PWMs). In addition, ModENCODE EcR ChIP data are shown with a blue line, for L3 (modEncode_2640), WPP 4–5 h (modEncode_3398), WPP 10–11 h (modEncode_2641), WPP 30–33 h (modEncode_2642).




Figure 5. EcR functionally interacts with *hth + tsh* in inducing tissue overgrowth. Adult heads (A,C lateral and A',C' dorsal views) and eye discs (B,D) of *optix > GFP:hth + tsh + GFP* (A,B) and *optix > GFP:hth + tsh + EcRB1* (C,D) (note that both genotypes harbor equal number of UAS-transgenes). Co-overexpression of EcRB1 enhances the overgrowth of lateral head cuticle and eye disc tissue. Comparison between eye discs overexpressing a dominant-negative form of the EcRB1 (E: *optix > GFP + EcRB1-DN*) and the co-overexpression of EcRB1-DN with *hth + tsh* (F: *optix > GFP:hth + tsh + EcRB1-DN*). Expression of EcRB1 causes a mild reduction in eye disc size (E). Coexpression of EcRB1-DN suppresses the overgrowth produced by *hth + tsh* (compare F with B). Discs are stained with anti-GFP (green) and anti-Eya (red) antibodies.

RNAis assayed against either of the two genes produced any significant phenotypic alteration on their own (Suppl. Fig. 6). However, the disc phenotypes were not identical: while in *optix > hth + tsh + Hr46-RNAi* the portion of differentiating retina (marked by Eya-only cells) was almost totally obliterated (Fig. 6A,B'), in *optix > hth + tsh + ftz-f1-RNAi* there was a moderate, but consistent rescue of the Eya-expressing retina (Fig. 6A,D'). The co-overexpression of *Hr46* or *ftz-f1* produced the opposite effects: a clear reduction of the disc size (Fig. 6A,C,E) and a total obliteration of the retina. This obliteration could derive, in part, from the fact that the expression of *Hr46* (UAS-DHR3 RB) or *ftz-f1* (UAS- β ftz-f1) on their own resulted in approximately 40% and 60% reduction in adult eye size, respectively (Suppl. Fig. 6). In all, these experiments proved that *EcR*, *Hr46* and *ftz-f1*, which are regulated transcriptionally by *hth + tsh*, were functionally required for their synergistic effect on growth.

In addition, our transcriptomic/bioinformatics analysis suggested that some, or all of these nuclear receptors might be exerting their function through the regulation of cell cycle genes. This implied that *EcR*, *Hr46* and/or *ftz-f1* should have the potential to regulate the proliferation rates of cells anterior to the MF, where *hth* and *tsh* are normally coexpressed. Recent work indicates that indeed ecdysone is required for the proliferation of imaginal discs⁴⁷, supporting this notion. To test specifically if either *Hr46* or *ftz-f1* affect proliferation, we monitored the expression of the G2/mitotic cyclin *cyclin-B* (*cycB*) and the mitotic rate (using the mitotic marker phospho-Histone H3, PH3) of undifferentiated cells in *optix > Hr46*, *optix > ftz-f1* and *optix > ftz-f1-RNAi* (Fig. 7). In control discs (*optix > GFP*), proliferation is patterned: it is mostly restricted to progenitors, located at the far anterior of the disc, which express *CycB* and are mitotically active. Closer to the MF, cells stall their cell cycle transiently in G1, so they lose *CycB* and do not undergo mitosis (Fig. 7A). In *optix > Hr46* discs, though, the density of mitotic (PH3-positive) cells increased dramatically and the *CycB* gap anterior to the MF narrowed or disappeared, indicating an increased and continuous proliferation (Fig. 7B,E). Next, we tested *ftz-f1*. Overexpression of *ftz-f1* (*optix > ftz-f1*) resulted in a strong decrease in the density of PH3 cells in the anterior disc and a widening of the *cycB* gap anterior to the MF (Fig. 7C,E). While in the contrary experiment, *ftz-f1* attenuation (*optix > ftz-f1-RNAi*) increased anterior proliferation, and the *cycB* gap narrowed (Fig. 7D,E). These results indicate that both *Hr46* and *ftz-f1* have the potential to act as cell cycle regulators during eye disc development, and that they have opposing effects on proliferation.

Hr46/DHR3 and *ftz-f1* are regulated by Hth + Tsh. So far, four sets of results indicated that *Hr46* could be one of the key players in the response of cells to the combined expression of *hth* and *tsh*: (1) its transcription was specifically downregulated in *hth + tsh* discs; (2) potential binding sites for *Hr46* were found enriched in CREs linked to differentially expressed genes characterized as cell cycle regulators; (3) *Hr46* functionally interacted with *hth + tsh* and showed the capacity to regulate progenitor proliferation; and (4) Hth-binding plus FAIRE-seq data suggested that *Hr46* was a Hth direct target. If *Hr46* regulation were direct, and taking into account that globally *Hr46* was downregulated by *hth + tsh*, we expected *Hr46* to be repressed by *hth + tsh* in a cell-autonomous manner. First, we characterized *Hr46* expression during third larval stage to, then, check the effect of *hth + tsh* expressing clones on its expression. During the third (and last) larval period (L3), the




Figure 6. Nuclear receptors *Hr46* and *ftz-f1* functionally interact with *hth + tsh* in inducing tissue overgrowth. L3 eye discs, stained for GFP and Eya (upper panel) and lateral views of adult heads (lower panels) of the indicated genotypes (note that all genotypes harbor equal number of UAS-transgenes). RNAi-mediated attenuation (B) or overexpression (C) of *Hr46* enhances or suppresses, respectively, the *hth + tsh*-induced eye disc overgrowth. In adults, however, while *Hr46* attenuation enhances the tissue overgrowth/loss of eye (B'), its overexpression reduces the tissue overgrowth, but without rescuing retina differentiation (C'). RNAi-mediated attenuation of *ftz-f1* (D) or overexpression (E) enhances or suppresses, respectively, the *hth + tsh*-induced eye disc overgrowth. In this case, *ftz-f1* attenuation partly rescues the eye reduction of *hth + tsh* individuals (D'). Co-overexpression of *ftz-f1* suppresses the lateral cuticle overgrowth, without rescuing retina differentiation (E').

expression of *Hr46*, monitored with an anti-*Hr46* antiserum, builds up (Suppl. Figure 9). During early L3, *Hr46* is expressed weakly and ubiquitously in the eye disc. As differentiation moves across the disc, *Hr46* levels increase straddling the MF, peaking anterior to it. This expression is in agreement with ecdysone signaling being active in this region of the disc during L3 (Fig. 3 and ref. 51). Notably, its expression is exclusive to that of *Hth*. Only at the L3-pupal transition, *Hr46* levels raise uniformly throughout the disc, coinciding with the ecdysone pulse that triggers this molting (Suppl. Figure 9). Therefore, during most of the retinal differentiation period, the expression of *hth* and *Hr46* is complementary (Fig. 8A). Since *tsh* expression overlaps *hth* in this anterior region of the eye primordium¹⁰, the complementarity between *hth* and *Hr46* was consistent with *Hr46* being repressed by *hth + tsh*. To test this point, we induced cell clones, marked with GFP, expressing either *hth* or *tsh* alone, or *hth + tsh*. Only *hth + tsh* clones reduced the levels of *Hr46*, and did so in a cell-autonomous manner (Fig. 8B–D), which agrees with a direct regulation of *Hr46* by *hth + tsh*.

Another NR differentially transcribed in *hth + tsh* cells and showing functional interactions with these two transcription factors is *ftz-f1*. Using *in situ* hybridization with a probe common to all *ftz-f1* isoforms (Fig. 8E–E'), we detected *ftz-f1* transcription in the anterior portion of the eye disc (Fig. 8E,E'), where undifferentiated cells reside. Signal in the differentiated eye is lower. To test that this expression is specific, we hybridized also *optix > ftz-f1* discs and found that, as expected, *ftz-f1* transcription was enhanced in the *optix* domain –i.e. anterior disc (Fig. 8E''). When *hth + tsh* expression is maintained in *optix > hth + tsh*, *ftz-f1* transcription was substantially increased in the overgrowing tissue (Fig. 8E'''), confirming that *hth + tsh* can enhance *ftz-f1* transcription.

Potential significance of the *hth + tsh* control of nuclear receptors in human cancers. The over-proliferative phenotype caused by co-expression of *hth* and *tsh* in the *Drosophila* eye prompted us to ask whether co-occurrence of their homologues, MEIS and TSHZ, could also be detected in human tumors. A role for MEIS1 in hematopoietic and solid tumors is established, but a potential relationship with TSHZ genes had not been previously explored. Analysis of 116 public datasets on the R2 Genomics Analysis and Visualization Platform (<http://r2.amc.nl>), representing most major tumor types, showed that MEIS1 and TSHZ1–3 are widely expressed in solid tumors (Suppl. Table 4A). In addition, significant positive correlation between MEIS1 and TSHZ1, TSHZ2, or TSHZ3 mRNA expression was found in several major solid tumor types (in 46, 56, and 60 of 91 datasets, respectively; Suppl. Tables 4B and 5). OncoPrint analysis of these tumor types datasets showed that MEIS1 and TSHZ1–3 often have mRNA co-overexpression and/or DNA copy number gain in cancer versus normal tissue (Suppl. Tables 4C and 6). Suppl. Figure 10 shows examples for MEIS1 and TSHZ2 in breast and colon cancer with R2 (A,B) and OncoPrint (C–F). These data suggest that the synergistic growth-inducing capacity of *hth* and *tsh* in *Drosophila* has a parallel in oncogenic coordinated over-expression of MEIS1 and TSHZ genes in human cancer.

Our global characterization of the *hth + tsh*-induced overgrowths in *Drosophila* pointed to a crucial role for three nuclear receptors, *EcR*, *Hr46* and *ftz-f1*. In addition, previous work had shown that *hth* and *tsh* directly interact with *yki*, the co-activator of the Salvador-Warts-Hippo pathway, and that this interaction was necessary




Figure 7. Altering *Hr46* and *ftz-f1* expression regulates proliferation of eye progenitors. L3 eye discs of the indicated genotypes (A–D) stained for cyclinB (cycB, green) and the mitotic marker PH3 (red). Merged and cycB signals are shown. Control discs are *optix*>+. PH3-positive cells were counted in the anterior region of the eye disc, where undifferentiated progenitors reside (outlined in white in A). In (A') the double-headed arrow marks the width of the G1-arrested domain (see text for details). (E) Statistical analysis of the mitotic density (PH3 + cells/anterior area) indicates that overexpression of *Hr46* and RNAi-mediated attenuation of *ftz-f1* result in increased proliferation. Note that in both genotypes the G1 arrested domain is narrower than in the control (especially for *optix* > *Hr46*; B). On the contrary, overexpression of *ftz-f1* results in reduced proliferation.

for the pro-proliferative action of this TF combination^{11,59}. We therefore searched for similar expression signatures in human tumors with MEIS1 and TSHZ co-overexpression on the R2 Platform. We found significant and consistent correlations between MEIS1 and RORA, NR5A2, or YAP1 (the human *Hr46*, *ftz-f1*, and *yki* homologues, respectively) in major solid tumor types like breast, colon, and lung cancer (Suppl. Table 7, see also Suppl. Table 5). We had expected a *negative* correlation for RORA, as *Hr46* showed a clear repression in *hth* + *tsh* cells. However, this difference may be explained either by differences in the “tumoral stage” between the *Drosophila* overgrowths and human tumors -for instance, the *Drosophila* *hth* + *tsh* overgrowths are not metastatic (not shown)- or by species-specific differences in the mechanisms driving overproliferation. When globally considered, our results identify a parallelism between the progenitor proliferation program controlled by *hth* + *tsh* and the MEIS1/TSHZ-associated oncogenic program.




Figure 8. The expression domains of *hth* and *Hr46* are complementary and co-expression of *hth* + *tsh* repress *Hr46*. *hth:YFP* late L3 disc stained with anti-*Hr46* (A) and the corresponding optical cross-section (A'). The arrow marks the morphogenetic furrow (MF) and the dashed line marks the boundary between *Hth* and *Hr46* expression. Clones overexpressing *hth* (B,B'), *tsh* (C,C') or both (D,D'), marked by GFP (and outlined with the red dashed line), were induced in the eye imaginal disc at 48–72 hours after egg laying. Discs are stained with anti-*Hr46*. (E–E''') *in situ* hybridization with *ftz-f1* anti-sense probe in third-instar eye discs from *optix > GFP* (E'), *optix > βfyz-f1* (E'') and *optix > hth, tsh* (E''') larvae. *ftz-f1* sense probe was used as a control in *optix > GFP* eye discs (black dashed line outlines the disc) (E). *ftz-f1* is transcribed in control eye discs in a dynamic pattern, with high expression in the anterior region and lower levels in the most posterior region. Red dashed lines mark the region where *ftz-f1* expression is expected to be higher in *optix > βfyz-f1* discs. *hth* + *tsh* discs show higher *ftz-f1* levels (black arrowheads mark the regions with especially strong *ftz-f1* transcription).

Discussion

During organ development and tissue homeostasis cell numbers are tightly controlled. This control is exerted on progenitors, the main proliferating cell population, through their expression of transcription factors which, forming regulatory networks, also preserve them in an undifferentiated state. In this paper we have investigated in *Drosophila* how the input of two conserved transcription factors, which are part of the eye gene network, *hth* and *tsh*, regulate proliferation of eye progenitors.

Integrated analysis of the transcriptome, chromatin accessibility and TF binding motif enrichment data from *hth* + *tsh*-induced overgrowths revealed a transcriptional network related to the EcR (Ecdysone Receptor) pathway. At the molting periods, pulses of the active form of the ecdysone hormone, 20-hydroxyecdysone, the major estrogen hormone in insects, trigger the response of the EcR pathway. This response is characterized by stereotypic, staggered expression changes in nuclear receptors that regulate the entry into metamorphosis⁴⁶. Specifically, the pattern of nuclear receptor gene expression in *hth* + *tsh* cells, characterized by high *EcR/ftz-f1* and low *Hr46/Blimp-1* is typical of a low/moderate ecdysone signaling⁴⁷. During eye development in *Manduca sexta*, moderate levels of ecdysone are required for stimulation of eye proliferation during larval stages. However, low levels of ecdysone arrest cells in the G2 phase, while the high pulse of ecdysone released later during development is responsible for cell cycle exit^{60,61}. A similar situation might be happening during *Drosophila* eye development. In this case, forced maintenance of *hth* + *tsh* might induce cell proliferation through the maintenance of a moderate activity of the ecdysone pathway. Four sets of facts strongly suggest that the high *EcR/ftz-f1*-low *Hr46/Blimp-1* pattern of nuclear receptors is instrumental in triggering the *hth* + *tsh*-mediated tissue overgrowth. First, modulating the expression or activity of *EcR*, *Hr46* or *ftz-f1* affects the *hth* + *tsh*-induced overgrowths in non-additive

ways; second, changes in nuclear receptors are paralleled by increased expression of cell cycle genes; third, CREs linked to these cell cycle genes show an enrichment of Hr46/ftz-f1-type DNA binding motifs, pointing to a direct regulatory linkage; and fourth, we have observed that *Hr46* and *ftz-f1* have the potential to regulate progenitor proliferation. Therefore, we posit that overexpression of *hth* + *tsh* results in a specific pattern of nuclear receptor transcription. Part of this may stem from a potential direct regulation by *Hth* and *Tsh* of genes such as *Hr46*. Then, expression changes along the nuclear receptor cascade would affect a large number of cell cycle-related genes, which show significant association of nuclear receptors DNA-binding motifs to their CREs, thus leading to sustained tissue growth. We have noted a discrepancy between the direction of the functional interactions of *Hr46* and *ftz-f1* with *hth* + *tsh*, and the capacity to enhance (*Hr46*) or decrease (*ftz-f1*) cell proliferation when assayed individually. For example, co-overexpression of *Hr46* suppresses the *hth* + *tsh* overgrowth (Fig. 6), suggesting an anti-proliferative role. However, overexpression of *Hr46* alone increases proliferation rates. We do not have an explanation for this discrepancy. However, the *EcR* pathway is very complex, with nested temporally delayed feedbacks. With this complexity, it is difficult a priori to predict the direction of the interactions. In addition, although not measured in this study, variations in the rate of apoptosis may impact final organ size. Still, we believe the we present solid evidence indicating that *hth* + *tsh* promote a specific pattern of nuclear receptor expression; that these nuclear receptors functionally interact with *hth* + *tsh* in modulating the overgrowth these TFs induce in progenitor-like cells and that *Hr46* and *ftz-f1* are capable of modulating the proliferative pace of undifferentiated progenitors. Similar discrepancies had been described in other model systems. While it has been shown that increased expression of ROR β , one of the *Hr46* homologues, in rat retinal progenitor cells results in an increase in the number of large cell clones⁶², ROR α is normally down-regulated or hypo-activated in breast cancer cells (reviewed in ref. 63).

We have noticed within transcriptional profiling data of Yki overexpressing wing primordia, reported in Suppl. Table 4 by Oh and co-workers⁶⁴, a similar signature of differential expression of nuclear receptors as the one we find in *hth* + *tsh* overexpressing eye discs. This similarity may stem from the fact that, in the eye, *Hth* and *Tsh* have been shown to be direct partners of Yki¹¹, the transcriptional coactivator of the Hippo tumor suppressor pathway⁶⁵. In an epithelial cancer model in the *Drosophila* eye disc characterized by loss of function of *scribbled* (an apico-basal cell polarity regulator) and overexpression of *abrupt* (a BTB-zinc finger transcription factor), a similar pattern of expression was observed, with reduced levels of *Hr46* and *Blimp-1* and high levels of *ftz-f1* (in this case *EcR* levels were not affected)⁶⁶. Interestingly, ChIP-seq data analysis showed that *Abrupt* is able to directly regulate *Hr46*, *Blimp-1*, *ftz-f1* and *EcR*⁶⁶. A similar repression of ecdysone response genes has been also described in the *Drosophila* ovary, where *abrupt* interacts with *taiman*, a steroid hormone receptor co-activator⁶⁷. In our work, *abrupt* expression levels were up-regulated in eye discs where there was forced maintenance of *hth* or *hth* + *tsh* (with a fold change of approximately 2 in both situations), suggesting also a role in the control of the expression of nuclear receptors in progenitors. More recently, overexpression of *taiman* and *ftz-f1* was also shown to be present in a model of invasive cancer driven by RAS in the eye disc⁶⁸. In the cancer models mentioned above, a role for the Hippo pathway has been described^{66,68}. Therefore, a similar nuclear receptor (and probably *abrupt*) expression pattern might be a general feature of Hippo-related tissue overgrowth. Whether this is also the case in human tumors where components of the Hippo-YAP pathway are mutant needs to be investigated.

One interesting aspect of the global regulatory response elicited jointly by *hth* and *tsh* is that this response is quantitative, not qualitative. That is, expression of *hth* + *tsh* drives the transcriptional upregulation of many genes but with minor changes in the profile of their CRE activity, as measured by open chromatin profiling. This suggests that *hth* + *tsh* operate through CREs that are already active (i.e., open chromatin), rather than by inducing the *de novo* “opening” of new ones. This behavior contrasts with results analyzing the transcriptional response and CRE activity profiles in eye tumors in the *rasV12/scrib* model. Here, the transcriptional changes were paralleled by qualitative changes in CRE activity, with the *de novo* opening of hundreds of promoters and enhancers⁵⁷. This fact seems related to the different nature of the tissue overgrowths in each of the two genotypes. While *hth* + *tsh* expression drives continuous proliferation of progenitors (i.e. hyperplastic growth), *rasV12/scrib* tissues are metastatic.

The dual control of cell fate and proliferation makes organ specification TFs a “vulnerable link”. Particularly, it is often the case that mutations affecting the expression of an organ- or cell-type selector TF result in cancer developing from this same organ. Examples of this are the eye and pancreas TF Pax6 in retinoblastoma and pancreatic cancer^{69,70}; myogenic MyoD1 in rhabdomyosarcoma⁷¹; hematopoietic progenitor TFs MEIS1 and TAL1 in leukemia^{72,73}; neural crest SOX10 and MITF in melanoma^{74,75} or GATA3 in breast cancer⁷⁶. And more generally, many cancer driver mutations affect TFs⁷⁷. In particular, the oncogenic role of MEIS1 has been documented. Here, we have established for the first time that MEIS1 and TSHZ occur in coordinated over-expression in several major solid tumors types, an association that may recapitulate the functional synergism of *hth* and *tsh* in the fly eye primordium.

Co-overexpression of *hth* + *tsh* results in transcriptional changes and functional interactions that bear similarity with those observed in tumors where Estrogen Receptor alpha (ER α) and NR5A2/LRH-1 (*ftz-f1* homologue) play important roles, such as breast cancer^{78–80}. Interestingly, it has been reported that NR5A2 expression is also increased in pancreatic cancer (see also Suppl. Tables 5 and 7) where it promotes cell growth through stimulation of major cell cycle regulators cyclin D1, cyclin E1 and c-Myc⁸¹, and that NR5A2/LRH-1 represses the cell cycle inhibitor p21⁸². In addition, through ChIP-seq and gene expression experiments, the estrogen receptor (and other nuclear receptors, such as the androgen receptor) has been shown to directly regulate genes involved in cell cycle progression^{83–86}. The similarities between the *Drosophila* mechanism described here and the expression correlations found in human tumors suggest a scenario where MEIS1 and TSHZ genes, if co-overexpressed, might be driving transformation through the regulation of nuclear receptors which, then, would be translated into a general regulatory effect on many cell cycle-related genes.

Materials and Methods

GEO accession numbers. GSE65252 contains two series: RNA-seq (GSE65250) and FAIRE-seq (GSE65251) data.

Fly strains and genetic manipulations. All crosses were set up and raised at 25 °C under standard conditions. We used the UAS/GAL4 system for targeted misexpression⁸⁷. The following stocks were used: *optix2.3-GAL4* (gift from R. Chen, Baylor College of Medicine); *UAS-GFP*⁸⁸; *UAS-131-GFP*⁸⁹; *UAS-Flag-HA-tsh* (gift from C. M. Luque, Universidad Autónoma, Madrid, Spain); *yw, hs-FLP*¹²²; *act > y + > Gal4*⁹⁰ with a recombinant UAS-GFP transgene; Hth-YFP (CPTI-001356; Flannotator); EcRE-lacZ (Bloomington #4517). Fly stocks used for the screen are listed in Suppl. Table 3. *optix > GFP:hth* and *optix > tsh* larvae were collected from *optix2.3-GAL4* to *UAS-GFP:hth* or *UAS-HA:tsh* crosses. For RNA-seq and FAIRE-seq experiments, *optix > GFP:hth + tsh* larvae were obtained directly from an *optix2.3-GAL4,UAS-Flag-HA-tsh;UAS-131-GFP*^{hth}/*SM6^{TM6B}* stock (“hth + tsh_stock”; biological replicate #1) or derived from the cross of *optix2.3-GAL4,UAS-Flag-HA-tsh; + / SM6^{TM6B}* to *UAS-GFP:hth* (“hth + tsh_cross”; biological replicate #2). As FAIRE-seq control we used the data sets previously obtained in the laboratory using two reference strains, Oregon-R (wild type) and *FRT82B* (Flybase).

All lines listed in the Suppl. Table 3 (RNAi, overexpression and dominant negative) were crossed to the *optix2.3-GAL4* driver line and the *optix2.3-GAL4,UAS-Flag-HA-tsh;UAS-131-GFP*^{hth}/*SM6^{TM6B}* stock. All crosses were maintained at 25 °C. For Hr46 we tested the efficacy of three anti-Hr46 RNAi lines using an anti-Hr46 antiserum (data not shown). In all cases, we detected a reduction of the Hr46 signal, the reduction being most extreme for line 106837. Flies were observed under a LEICA MZ 9.5 stereomicroscope and pictures of heads from adults of each genotype were taken with a LEICA DFC320 digital camera.

Random ectopic expression clones were generated using the flip-out method⁹⁰. *yw, hs-FLP*¹²²; *act > y + > Gal4*; *UAS-GFP*/*TM6B* females were crossed to *UAS-Flag-HA-tsh*, *UAS-131-GFP*^{hth} or *UAS-Flag-HA-tsh;UAS-131-GFP*^{hth} males. Clones were induced by heat shock (20 min at 37 °C) between 48 h and 72 h AEL (after egg laying) and then maintained at 25 °C. Clones were positively marked with GFP.

Immunostaining. Eye-antennal imaginal discs from wandering third instar larvae were dissected and fixed according to standard protocols. Primary antibodies used were: mouse anti-Eya 10H6 at 1:100 (Developmental Studies Hybridoma Bank, DSHB), rabbit anti-βGal at 1:1000 (Cappel), mouse anti-CycB F2F4 at 1:100 (DSHB), rabbit anti-PH3 at 1:1000 (Sigma), rat anti-ELAV 7EBA10 at 1:1000 (DSHB), rabbit anti-HA 9110 at 1:1000 (Abcam), guinea pig anti-Hth at 1:3000⁹¹, rabbit anti-Hr46 at 1:50 (gift from Carl S. Thummel, University of Utah School of Medicine), mouse anti-CycA A12 at 1:10 (DSHB), mouse anti-Dacapo NP1 at 1:4 (DSHB), mouse anti-CycE at 1:20 (gift from Helena Richardson). Alexa-Fluor conjugated secondary antibodies and rhodamine phalloidin (R415) were from Molecular Probes. Images were obtained with the Leica SP2 confocal system and processed with Adobe Photoshop.

RNA probe synthesis. A ftz-f1 digoxigenin (DIG)-labeled RNA probe was synthesized through two PCR reactions using ftz-f1-specific primers with GC-enriched tails (5'-GGCCGCGGCAGTGGCAATAATG GCAATC-3' and 5'-CCGGCCGCGATCCTATTCAGCCTTG-3') and universal primers (5'-GAGAATTCTAA TACGACTCACTATAGGGCCGCGG-3' and 5'-AGGGATCCTAATACGACTCACTATAGGCCCGGC-3'). PCR products were purified from gel using a Qiagen Kit. Using the DIG RNA Labelling Kit (SP6/T7) from Roche, the RNA probe was synthesized with T7 RNA polymerase. After synthesis, precipitation of the probe was done using LiCl and ethanol. The probe was then resuspended in DEPC treated water.

In situ hybridization. Larvae were dissected in cold PBS, fixed in 3, 7% paraformaldehyde (in PBS) during 20 minutes and refixed in 3, 7% paraformaldehyde (in PBT) during 20 minutes, always at room temperature. After fixation, discs were washed at room temperature in PBTween (PBS with 0, 1% Tween) during 25 minutes (5 washes of 5 minutes each), in PBTween:Hybridization solution (1:1) during 5 minutes and in hybridization solution during 5 minutes. Hybridization solution (HS) contains formamide, 20xSSC, salmon sperm DNA 10 mg/ml, Tween20 (10%) in DEPC treated water. Then, discs were prehybridized for 1 hour at 60 °C in HS. The hybridization reaction was carried out overnight at 60 °C with a hybridization mix (HS, single stranded DNA (4, 6 mg/ml) and labeled probe). After incubation, discs were washed in HS during 20 minutes at 60 °C, in HS:PBT (1:1) during 20 minutes at 60 °C and in PBT during 1 hour (3 washes of 20 minutes each) at room temperature. Afterwards, discs were incubated for 2 hours at room temperature with anti-digoxigenin antibody coupled to alkaline phosphatase (Roche Diagnostics) diluted 1:1000 in PBT. Excess antibody was removed by washing with PBT (a quick wash and then three washes of 20 minutes each) at room temperature. Discs were then equilibrated for 10 minutes (two washes of five minutes each) at room temperature in AP Buffer (fresh solution containing 1 M Tris pH 9, 5, 1 M MgCl₂, 4 M NaCl, Tween20 (10%) in DEPC-treated water). Color development was performed at 37 °C (5 minutes) in AP Buffer containing NBT and BCIP. Staining was stopped with PBT (two washes of 5 minutes each) at room temperature. Afterwards discs were post-fixed in 3, 7% paraformaldehyde in PBTween, washed in PBTween and cleared in ethanol.

Scanning electron microscopy (SEM). Female flies were transferred to 75% ethanol and equilibrated for 24 hours at room temperature. Flies were dehydrated through ethanol series (80%, 90%, 95% and twice 100%; 12–24 hours each step). Flies were then air-dried and mounted onto SEM stubs covered with carbon tape and sputter coated with gold (Edwards Six Sputter). Images were obtained using a JEOL 6460LV scanning electron microscope.

Quantification of PH3⁺ cells. Third instar eye imaginal discs from control, *optix > Hr46* (UAS-DHR3RB), *optix > α ftz-f1*, and *optix > ftz-f1 RNAi* (#2959) were stained with anti-PH3 and anti-CycB. The anterior area of the eye disc was defined by creating a surface and the PH3⁺ cells first were automatically identified and then manually curated. Finally, the number of PH3⁺ cells that fall within the created surface were detected. This analysis was made using the IMARIS x64 7.7.2 software. The ratios between the PH3⁺ cells and the anterior area ($n = 7-10$) were calculated and represented as dots (control), triangles (*optix > Hr46*), plus (*optix > ftz-f1*) and cross (*optix > ftz-f1 RNAi*) and the means were represented as horizontal bars. The graphical output was generated using R. Statistical significance was determined using an ANOVA test.

RNA-Seq. Wandering third instar larvae raised at 25 °C under standard conditions were dissected in PBS to extract 50 eye-antennal imaginal discs. RNA was extracted using the RNAqueous micro kit (Ambion). RNA quality was checked using Agilent RNA 6000 Nano Kit. RNA libraries were prepared for sequencing using a standard Illumina TruSeq protocol. Libraries were validated quantitatively (Qubit) and qualitatively (Agilent DNA 1000 Kit, Agilent Technologies 2100 Bioanalyzer).

FAIRE-Seq. 100 eye-antennal imaginal discs from wandering third instar larvae raised at 25 °C under standard conditions were dissected in PBS. The imaginal discs were first dissected, fixed and lysed. The eye-antennal discs were then uncrosslinked and sonicated. DNA purification was achieved by phenol chloroform extraction (MaXtract High Density Kit). DNA libraries were prepared for sequencing using a standard protocol. Libraries were validated quantitatively (Qubit) and qualitatively (Agilent High Sensitivity DNA Kit, Agilent Technologies 2100 Bioanalyzer).

RNA-seq and FAIRE-seq reads preprocessing. Reads containing residuals of adapters sequences were discarded (FastX clipper version 0.013 with option -M15). Quality control assessment on the reads was performed using the software FastQC (version 0.9), checking for PHRED quality >20 and different primer contaminations. Reads passing the filtering were mapped against *D.melanogaster* FlyBase genome release 5 with TOPHAT v2.0 (default parameters)⁹².

RNA-seq differential expression analysis. To compute gene expression levels, we performed HTSeq (option *str = no*)⁹³. Only uniquely mapped reads falling in exons based on the species-specific FlyBase annotation *D.melanogaster* 5.45 were considered.

Differential expression analysis between HTH + TSH (two replicates) and wt (one replicate) was performed using the Bioconductor package DESeq version 1.10.1 (R version 2.15). For contrasts with no replicates available, such as HTH vs wt and TSH vs wt, we utilized the parameters *method = 'blind'*, *shareMode = 'fit-only'* to estimate dispersions across samples. Genes presenting low expression across samples, namely, less than 1RPKM in more than 3 samples were not considered for differential expression analysis.

FAIRE-seq analysis. Pre-processed reads were mapped against *D. melanogaster* reference genome release 5 using Bowtie2⁹⁴. Open chromatin levels were computed as the number of reads mapping within *Drosophila* pre-defined regions³³ using HTSeq⁹³, parameter (*str = no*). The set of pre-computed *D. melanogaster* regulatory regions are defined by a thorough genome-cut which considers sequence conservation, exon skipping and insulator class I binding³³.

FAIRE-seq differential expression. Regions with less than 10RPKM in three samples were excluded for differential open chromatin analysis. Differential open-chromatin was performed as described in the RNA-seq differential expression analysis section. The main difference is that instead of genes we use as features regulatory regions ids. The contrast performed defined differential open regions between HTH + TSH (two replicates) and wild-type (two replicates).

Association between genes and open-chromatin regions. Peaks were assigned to a gene if they were falling 5-kb upstream of its TSS or either limited by the nearest upstream gene, in its intronic regions or in 5-kb downstream of a gene limited by the closest downstream gene.

Association between open-chromatin and HTH binding. ChIP for HTH, Sd, Yki transcription factors in late third instar (wandering) larvae has been performed by ref. 59. ChIP locations were translated to regulatory region ids if they were presenting an overlap fraction of 40% (*overlapSelect f = 0.4*).

To assess whether differential open regions between HTH + TSH and wildtype were associated with HTH binding we compared the log₂ fold change of FAIRE regions in bound and not bound HTH regions. Wilcoxon signed-ranked test was performed to assess its statistical significance.

Co-expression using Pavlidis Template Matching. Pavlidis Template Matching⁹⁵ was used to find genes showing a similar or opposite expression profile of EcR (by starting from EcR expression template, *p-value < 0.01*).

Gene Ontology term enrichment. Gene ontology enrichment for different gene sets was computed using the tool FlyMine⁹⁶, whereas ranked lists of genes were inputted in GOrilla⁹⁷.

Motif enrichment discovery. Motif discovery was performed with the tools *i-cistarget*³³ and its Cytoscape version, *iRegulon*⁹⁸. In brief it searches for overrepresented motifs in a set of co-expressed genes and across evolution. The following parameters were used: motif collection version 2 (6385 position weight matrices) and region mapping equal to 5 Kb upstream and full transcript. *i-cistarget* is a hybrid method that allows finding both known

and new motifs. The new motifs are also represented as position weight matrices and are a collection of thousands of “candidate” motifs found by other studies for which the binding factor is yet unknown. This collection includes highly conserved words, but also enriched words discovered in chromatin binding data from ENCODE and modENCODE. In addition, *i-cistarget* allows finding motifs from orthologous factors, including yeast, mouse, and human, thereby greatly expanding the number of possible TFs. Finally, the number of *Drosophila* transcription factors without a possible motif is very limited, thanks to recent high-throughput approaches⁹⁹, and the porting of binding motifs from other species⁵².

Gene Set Enrichment Analysis. We used the tool Gene Set Enrichment Analysis (GSEA)¹⁰⁰ to assess if open-chromatin regions are enriched in either up or down-regulated genes at the gene expression level (hth + tsh *versus* control). Therefore, we inputted two sets of genes with significantly up or down open-chromatin regions and a ranked list of genes based on the $-\log p$ value from the differential expression analysis.

mRNA expression and DNA copy number analysis in human cancer datasets. Affymetrix datasets of 103 different studies on human cancer types were retrieved from the public Gene Expression Omnibus (GEO) dataset on the National Center for Biotechnology Information (NCBI) website¹⁰¹. We selected studies using the Affymetrix Gene Chip Human Genome U133 Plus 2.0 array platform (Affymetrix, Santa Clara, CA) since this was the most common platform in the database. Also, probes for the *TSHZ1-3* genes are not present on earlier versions of the Affymetrix platform. Annotations and clinical data for the datasets analyzed are available through their GEO ID's (Suppl. Table 3) from <http://www.ncbi.nlm.nih.gov/geo/query/>. CEL data were downloaded, and analyzed as described¹⁰². Briefly, gene transcript levels were determined from data image files using GeneChip operating software (MAS5.0 and GCOS1.0, from Affymetrix). Samples were scaled setting the average intensity of the middle 96% of all probe-set signals to a fixed value of 100 for every sample in the dataset, to allow transcript level comparison between micro-arrays and between studies. The TranscriptView genomic analysis and visualization tool (<http://bioinfo.amc.uva.nl/human-genetics/transcriptview/>) was used to select probe-sets. These had to show unique mapping in an anti-sense position within a 3' exon and/or the 3' UTR of the gene. When multiple correct probe-sets were available for a gene, the probe-set with the highest average expression and amount of present calls for that dataset was considered as the best probe-set. These were: 204069_at (*MEIS1*), 210174_at (*NR5A2*), 226682_at (*RORA*), 242385_at (*RORB*), 223283_s_at (*TSHZ1*), 235815_at (*TSHZ2*), 223392_s_at (*TSHZ3*), and 224894_at (*YAPI*). When results of the best probe-set conflicted with other probe-sets for that gene, the data are not presented. Analyses on the GEO datasets Analyses were performed using R2; a genomics analysis and visualization platform developed in the Department of Oncogenomics at the Academic Medical Center, Amsterdam, The Netherlands (<http://r2.amc.nl>).

Statistical analysis of of mRNA expression and DNA copy number in human cancer. Correlations between *MEIS1* and other gene mRNA expression in R2 were calculated using a Pearson test on 2 log-transformed expression values (with the significance of a correlation determined by $t = R/\sqrt{(1 - r^2)/(n - 2)}$, where R is the correlation value and n is the number of samples, and distribution measure is approximately as t with $n - 2$ degrees of freedom). The Statistical Package for the Social Sciences software package for Windows (Version 13.0) was used for all statistical analyses. All numerical results are expressed as the mean value \pm S.E.M., and $P < 0.05$ was considered significant in all tests. For all tests on Oncomine (<http://www.oncomine.org>), the website standard settings were used, and values are shown as 2 log-median centered, with statistically significant differences determined by t-testing.

References

- Buckingham, M. & Rigby, P. W. Gene regulatory networks and transcriptional mechanisms that control myogenesis. *Dev Cell* **28**, 225–38 (2014).
- Gottgens, B. Regulatory network control of blood stem cells. *Blood* **125**, 2614–2620 (2015).
- Cvekl, A. & Ashery-Padan, R. The cellular and molecular mechanisms of vertebrate lens development. *Development* **141**, 4432–47 (2014).
- Arda, H. E., Benitez, C. M. & Kim, S. K. Gene regulatory networks governing pancreas development. *Dev Cell* **25**, 5–13 (2013).
- Peter, I. S. & Davidson, E. H. A gene regulatory network controlling the embryonic specification of endoderm. *Nature* **474**, 635–9 (2011).
- Amore, G. & Casares, F. Size matters: the contribution of cell proliferation to the progression of the specification *Drosophila* eye gene regulatory network. *Dev Biol* **344**, 569–77 (2010).
- Kumar, J. P. Retinal determination the beginning of eye development. *Curr Top Dev Biol* **93**, 1–28 (2010).
- Potier, D. *et al.* Mapping gene regulatory networks in *Drosophila* eye development by large-scale transcriptome perturbations and motif inference. *Cell Rep* **9**, 2290–303 (2014).
- Quiring, R., Walldorf, U., Kloter, U. & Gehring, W. J. Homology of the eyeless gene of *Drosophila* to the Small eye gene in mice and Aniridia in humans. *Science* **265**, 785–9 (1994).
- Bessa, J., Gebelein, B., Pichaud, F., Casares, F. & Mann, R. S. Combinatorial control of *Drosophila* eye development by eyeless, homothorax, and teashirt. *Genes Dev* **16**, 2415–27 (2002).
- Peng, H. W., Slattery, M. & Mann, R. S. Transcription factor choice in the Hippo signaling pathway: homothorax and yorkie regulation of the microRNA bantam in the progenitor domain of the *Drosophila* eye imaginal disc. *Genes Dev* **23**, 2307–19 (2009).
- Erickson, T., French, C. R. & Waskiewicz, A. J. Meis1 specifies positional information in the retina and tectum to organize the zebrafish visual system. *Neural Dev* **5**, 22 (2010).
- Azcoitia, V., Aracil, M., Martinez, A. C. & Torres, M. The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo. *Dev Biol* **280**, 307–20 (2005).
- Mercader, N., Tanaka, E. M. & Torres, M. Proximodistal identity during vertebrate limb regeneration is regulated by Meis homeodomain proteins. *Development* **132**, 4131–42 (2005).
- Bessa, J. *et al.* *meis1* regulates cyclin D1 and c-myc expression, and controls the proliferation of the multipotent cells in the early developing zebrafish eye. *Development* **135**, 799–803 (2008).
- Choe, S. K., Vlachakis, N. & Sagerstrom, C. G. Meis family proteins are required for hindbrain development in the zebrafish. *Development* **129**, 585–95 (2002).

17. Heine, P., Dohle, E., Bumsted-O'Brien, K., Engelkamp, D. & Schulte, D. Evidence for an evolutionary conserved role of homothorax/Meis1/2 during vertebrate retina development. *Development* **135**, 805–11 (2008).
18. Wang, G. G., Pasillas, M. P. & Kamps, M. P. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. *Mol Cell Biol* **26**, 3902–16 (2006).
19. Knoepfler, P. S., Calvo, K. R., Chen, H., Antonarakis, S. E. & Kamps, M. P. Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncoprotein E2a-Pbx1. *Proc Natl Acad Sci USA* **94**, 14553–8 (1997).
20. Orlovsky, K. *et al.* Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. *Proc Natl Acad Sci USA* **108**, 7956–61 (2011).
21. Zeisig, B. B. *et al.* Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. *Mol Cell Biol* **24**, 617–28 (2004).
22. Dardaei, L., Longobardi, E. & Blasi, F. Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis. *Proc Natl Acad Sci USA* **111**, E896–905 (2014).
23. Koller, K. *et al.* Nephroblastomas show low expression of microR-204 and high expression of its target, the oncogenic transcription factor MEIS1. *Pediatr Dev Pathol* **17**, 169–75 (2014).
24. Geerts, D., Revet, I., Jorritsma, G., Schilderink, N. & Versteeg, R. MEIS homeobox genes in neuroblastoma. *Cancer Lett* **228**, 43–50 (2005).
25. Geerts, D., Schilderink, N., Jorritsma, G. & Versteeg, R. The role of the MEIS homeobox genes in neuroblastoma. *Cancer Lett* **197**, 87–92 (2003).
26. Crijns, A. P. *et al.* MEIS and PBX homeobox proteins in ovarian cancer. *Eur J Cancer* **43**, 2495–505 (2007).
27. Tomoeda, M. *et al.* Role of Meis1 in mitochondrial gene transcription of pancreatic cancer cells. *Biochem Biophys Res Commun* **410**, 798–802 (2011).
28. Okumura, K. *et al.* Meis1 regulates epidermal stem cells and is required for skin tumorigenesis. *PLoS One* **9**, e102111 (2014).
29. Pan, D. Hippo signaling in organ size control. *Genes Dev* **21**, 886–97 (2007).
30. Thompson, B. J. & Cohen, S. M. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in *Drosophila*. *Cell* **126**, 767–74 (2006).
31. Nolo, R., Morrison, C. M., Tao, C., Zhang, X. & Halder, G. The bantam microRNA is a target of the hippo tumor-suppressor pathway. *Curr Biol* **16**, 1895–904 (2006).
32. Ostrin, E. J. *et al.* Genome-wide identification of direct targets of the *Drosophila* retinal determination protein Eyeless. *Genome Res* **16**, 466–76 (2006).
33. Herrmann, C., V de Sande, B., Potier, D. & Aerts, S. i-cisTarget: an integrative genomics method for the prediction of regulatory features and cis-regulatory modules. *Nucleic Acids Res* **40**, e114 (2012).
34. Potier, D., Atak, Z. K., Sanchez, M. N., Herrmann, C. & Aerts, S. Using cisTargetX to predict transcriptional targets and networks in *Drosophila*. *Methods Mol Biol* **786**, 291–314 (2012).
35. Tanaka-Matakatsu, M. & Du, W. Direct control of the proneural gene atonal by retinal determination factors during *Drosophila* eye development. *Dev Biol* **313**, 787–801 (2008).
36. Bhattacharya, A. & Baker, N. E. A network of broadly expressed HLH genes regulates tissue-specific cell fates. *Cell* **147**, 881–92 (2011).
37. Ligoxygakis, P., Yu, S. Y., Delidakis, C. & Baker, N. E. A subset of notch functions during *Drosophila* eye development require Su(H) and the E(spl) gene complex. *Development* **125**, 2893–900 (1998).
38. Brown, N. L., Sattler, C. A., Paddock, S. W. & Carroll, S. B. Hairy and emc negatively regulate morphogenetic furrow progression in the *Drosophila* eye. *Cell* **80**, 879–87 (1995).
39. Jarman, A. P., Sun, Y., Jan, L. Y. & Jan, Y. N. Role of the proneural gene, atonal, in formation of *Drosophila* chordotonal organs and photoreceptors. *Development* **121**, 2019–30 (1995).
40. Moses, K., Ellis, M. C. & Rubin, G. M. The glass gene encodes a zinc-finger protein required by *Drosophila* photoreceptor cells. *Nature* **340**, 531–6 (1989).
41. Hirose, F. *et al.* Isolation and characterization of cDNA for DREF, a promoter-activating factor for *Drosophila* DNA replication-related genes. *J Biol Chem* **271**, 3930–7 (1996).
42. Venkatesan, K., McManus, H. R., Mello, C. C., Smith, T. F. & Hansen, U. Functional conservation between members of an ancient duplicated transcription factor family, LSF/Grainyhead. *Nucleic Acids Res* **31**, 4304–16 (2003).
43. Frolov, M. V. & Dyson, N. J. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. *J Cell Sci* **117**, 2173–81 (2004).
44. Baonza, A. & Freeman, M. Control of cell proliferation in the *Drosophila* eye by Notch signaling. *Dev Cell* **8**, 529–39 (2005).
45. Firth, L. C. & Baker, N. E. Extracellular signals responsible for spatially regulated proliferation in the differentiating *Drosophila* eye. *Dev Cell* **8**, 541–51 (2005).
46. Thummel, C. S. Molecular mechanisms of developmental timing in *C. elegans* and *Drosophila*. *Dev Cell* **1**, 453–65 (2001).
47. Herboso, L. *et al.* Ecdysone promotes growth of imaginal discs through the regulation of Thor in *D. melanogaster*. *Sci Rep* **5**, 12383 (2015).
48. Agawa, Y. *et al.* *Drosophila* Blimp-1 is a transient transcriptional repressor that controls timing of the ecdysone-induced developmental pathway. *Mol Cell Biol* **27**, 8739–47 (2007).
49. Woodard, C. T., Baehrecke, E. H. & Thummel, C. S. A molecular mechanism for the stage specificity of the *Drosophila* prepupal genetic response to ecdysone. *Cell* **79**, 607–15 (1994).
50. Koelle, M. R. *et al.* The *Drosophila* EcR gene encodes an ecdysone receptor, a new member of the steroid receptor superfamily. *Cell* **67**, 59–77 (1991).
51. Brennan, C. A., Ashburner, M. & Moses, K. Ecdysone pathway is required for furrow progression in the developing *Drosophila* eye. *Development* **125**, 2653–64 (1998).
52. Weirauch, M. T. *et al.* Determination and inference of eukaryotic transcription factor sequence specificity. *Cell* **158**, 1431–43 (2014).
53. White, K., Ma, L. & Slattery, M. <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50338> (2008).
54. Slattery, M., Ma, L., Negre, N., White, K. P. & Mann, R. S. Genome-wide tissue-specific occupancy of the Hox protein Ultrathorax and Hox cofactor Homothorax in *Drosophila*. *PLoS One* **6**, e14686 (2011).
55. Giresi, P. G., Kim, J., McDaniell, R. M., Iyer, V. R. & Lieb, J. D. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. *Genome Res* **17**, 877–85 (2007).
56. Gaulton, K. J. *et al.* A map of open chromatin in human pancreatic islets. *Nat Genet* **42**, 255–9 (2010).
57. Davie, K. *et al.* Discovery of transcription factors and regulatory regions driving *in vivo* tumor development by ATAC-seq and FAIRE-seq open chromatin profiling. *PLoS Genet* **11**, e1004994 (2015).
58. Negre, N. *et al.* A cis-regulatory map of the *Drosophila* genome. *Nature* **471**, 527–31 (2011).
59. Slattery, M. *et al.* Divergent transcriptional regulatory logic at the intersection of tissue growth and developmental patterning. *PLoS Genet* **9**, e1003753 (2013).
60. Champlin, D. T. & Truman, J. W. Ecdysteroids govern two phases of eye development during metamorphosis of the moth, *Manduca sexta*. *Development* **125**, 2009–18 (1998).

61. Champlin, D. T. & Truman, J. W. Ecdysteroid control of cell proliferation during optic lobe neurogenesis in the moth *Manduca sexta*. *Development* **125**, 269–77 (1998).
62. Chow, L., Levine, E. M. & Reh, T. A. The nuclear receptor transcription factor, retinoid-related orphan receptor beta, regulates retinal progenitor proliferation. *Mech Dev* **77**, 149–64 (1998).
63. Du, J. & Xu, R. RORalpha, a potential tumor suppressor and therapeutic target of breast cancer. *Int J Mol Sci* **13**, 15755–66 (2012).
64. Oh, H. *et al.* Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. *Cell Rep* **3**, 309–18 (2013).
65. Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* Homolog of YAP. *Cell* **122**, 421–34 (2005).
66. Turkel, N. *et al.* The BTB-zinc finger transcription factor abrupt acts as an epithelial oncogene in *Drosophila melanogaster* through maintaining a progenitor-like cell state. *PLoS Genet* **9**, e1003627 (2013).
67. Jang, A. C., Chang, Y. C., Bai, J. & Montell, D. Border-cell migration requires integration of spatial and temporal signals by the BTB protein Abrupt. *Nat Cell Biol* **11**, 569–79 (2009).
68. Atkins, M. *et al.* An Ectopic Network of Transcription Factors Regulated by Hippo Signaling Drives Growth and Invasion of a Malignant Tumor Model. *Curr Biol* **26**, 2101–13 (2016).
69. Bai, S. W. *et al.* Pax6 regulates proliferation and apoptosis of human retinoblastoma cells. *Invest Ophthalmol Vis Sci* **52**, 4560–70 (2011).
70. Mascarenhas, J. B. *et al.* PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. *J Biol Chem* **284**, 27524–32 (2009).
71. Agaram, N. P. *et al.* Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. *Genes Chromosomes Cancer* **53**, 779–87 (2014).
72. Wong, P., Iwasaki, M., Somervaille, T. C., So, C. W. & Cleary, M. L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. *Genes Dev* **21**, 2762–74 (2007).
73. Chen, Q. *et al.* Coding sequences of the tal-1 gene are disrupted by chromosome translocation in human T cell leukemia. *J Exp Med* **172**, 1403–8 (1990).
74. Tani, M. *et al.* Isolation of a novel Sry-related gene that is expressed in high-metastatic K-1735 murine melanoma cells. *Genomics* **39**, 30–7 (1997).
75. King, R. *et al.* Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis. *Am J Pathol* **155**, 731–8 (1999).
76. Usary, J. *et al.* Mutation of GATA3 in human breast tumors. *Oncogene* **23**, 7669–78 (2004).
77. Aerts, S. & Cools, J. Cancer: Mutations close in on gene regulation. *Nature* **499**, 35–6 (2013).
78. Annicotte, J. S. *et al.* The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. *Oncogene* **24**, 8167–75 (2005).
79. Thiruchelvam, P. T. *et al.* The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. *Breast Cancer Res Treat* **127**, 385–96 (2011).
80. Chand, A. L., Herridge, K. A., Thompson, E. W. & Clyne, C. D. The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. *Endocr Relat Cancer* **17**, 965–75 (2010).
81. Benod, C. *et al.* Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. *Proc Natl Acad Sci USA* **108**, 16927–31 (2011).
82. Kramer, H. B. *et al.* LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner. *Nucleic Acids Res* **44**, 582–94 (2016).
83. Carroll, J. S. *et al.* Genome-wide analysis of estrogen receptor binding sites. *Nat Genet* **38**, 1289–97 (2006).
84. Cicatiello, L. *et al.* Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. *Am J Pathol* **176**, 2113–30 (2010).
85. Kwon, Y. S. *et al.* Sensitive ChIP-DSL technology reveals an extensive estrogen receptor alpha-binding program on human gene promoters. *Proc Natl Acad Sci USA* **104**, 4852–7 (2007).
86. Welboren, W. J. *et al.* ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. *EMBO J* **28**, 1418–28 (2009).
87. Brand, A. H. & Perrimon, N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401–15 (1993).
88. Bessa, J. & Casares, F. Restricted teashirt expression confers eye-specific responsiveness to Dpp and Wg signals during eye specification in *Drosophila*. *Development* **132**, 5011–20 (2005).
89. Casares, F. & Mann, R. S. A dual role for homothorax in inhibiting wing blade development and specifying proximal wing identities in *Drosophila*. *Development* **127**, 1499–508 (2000).
90. Struhl, G. & Basler, K. Organizing activity of wingless protein in *Drosophila*. *Cell* **72**, 527–40 (1993).
91. Casares, F. & Mann, R. S. Control of antennal versus leg development in *Drosophila*. *Nature* **392**, 723–6 (1998).
92. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–11 (2009).
93. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome Biol* **11**, R106 (2010).
94. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357–9 (2012).
95. Pavlidis, P. & Noble, W. S. Analysis of strain and regional variation in gene expression in mouse brain. *Genome Biol* **2**, RESEARCH0042 (2001).
96. Lyne, R. *et al.* FlyMine: an integrated database for *Drosophila* and *Anopheles* genomics. *Genome Biol* **8**, R129 (2007).
97. Eden, E., Navon, R., Steinfeld, L., Lipson, D. & Yakhini, Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. *BMC Bioinformatics* **10**, 48 (2009).
98. Janky, R. *et al.* iRegulon: from a gene list to a gene regulatory network using large motif and track collections. *PLoS Comput Biol* **10**, e1003731 (2014).
99. Zhu, L. J. *et al.* FlyFactorSurvey: a database of *Drosophila* transcription factor binding specificities determined using the bacterial one-hybrid system. *Nucleic Acids Res* **39**, D111–7 (2011).
100. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* **102**, 15545–50 (2005).
101. Barrett, T. *et al.* NCBI GEO: archive for high-throughput functional genomic data. *Nucleic Acids Res* **37**, D885–90 (2009).
102. Revet, I. *et al.* The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. *Exp Cell Res* **314**, 707–19 (2008).
103. Mahony, S. & Benos, P. V. STAMP: a web tool for exploring DNA-binding motif similarities. *Nucleic Acids Res* **35**, W253–8 (2007).
104. Frith, M. C., Li, M. C. & Weng, Z. Cluster-Buster: Finding dense clusters of motifs in DNA sequences. *Nucleic Acids Res* **31**, 3666–8 (2003).

Acknowledgements

We thank L Gilboa, R Barrio, A Ferrús, the Bloomington *Drosophila* stock Center and the VDRC for *Drosophila* strains. MN is an FCT fellow (Portugal). PSP is a recipient of a Portuguese “Investigator FCT” contract. We would also like to thank Antonella Iannini, the Advanced Light Microscopy Unit (CABD) and the SEM facility

at CITIUS (Univ. of Seville) for technical help and I Almodí and CS Lopes (IBMC, Portugal) for comments on the manuscript. Grants BFU2012-34324 and BFU2015-66040 (MINECO, Spain) to F.C. Grants from Research Foundation Flanders (FWO, grants G. 0640.13 and G. 0791.14), University of Leuven (OT/13/103) to SA. MNS was funded by a PhD fellowship from FWO.

Author Contributions

F.C. conceived the study. S.A. guided the high-throughput experiments and bioinformatics. M.N. carried out the experimental work. D.P. and M.N.S. carried out the bioinformatics analysis. D.G. carried out statistical analysis of human tumor data. All authors analyzed the data. F.C., S.A. and D.G. wrote the paper.

Additional Information

Supplementary information accompanies this paper at doi:[10.1038/s41598-017-04936-7](https://doi.org/10.1038/s41598-017-04936-7)

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017